Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up of ADP Adoptive Cell Therapies
NCT03391778Phase 1Enrolling by invitation
- Sponsor
- US WorldMeds
- Start
- Apr 2018
- Primary completion
- Apr 2032
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of ADP adoptive cell therapy in Neoplasm, sponsored by US WorldMeds. Primary endpoint: Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs) at 15 years. Started Apr 2018; status: enrolling by invitation.
02
Drugs
ADP adoptive cell therapy
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT03391778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391778.